This could be a key move for future growth.

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that ...

The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

June 17 (Reuters) - Biogen has struck a deal to acquire private biotechnology company RayThera for up to $1 billion, the companies said on Wednesday, as the U.S.-listed drugmaker seeks to expand its ...

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, ...

Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered ...

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biogen has agreed to pay $18.9 million to resolve a lawsuit alleging that it misled investors about the commercial readiness ​of the pharmaceutical company's Alzheimer's disease drug Aduhelm.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...